Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article Volume 5 Issue 11

Nanosponges: An Innovative Class of Drug Delivery System - Review

Tiwadi Shreya Shrinivas1, Jadhav Suryakant Bapurao1 and Tiwari Shailee Vijay2*

1Indira College of Pharmacy, Nanded, MH, India
2Durgamata Institute of Pharmacy, Parbhani, MH, India

*Corresponding Author: Tiwari Shailee Vijay, Durgamata Institute of Pharmacy, Parbhani, MH, India.

Received: June 10, 2021; Published: october 06, 2021



Productive targeted drug delivery systems are a massive construct from an extended time, however it’s been stricken by the advanced chemistry that’s concerned within the development of latest system. To overcome these problems, significant step have been taken in invention of nanosponges. Nanosponges are the tiny mesh like structure in which large variety of drugs can be filled. These have inclusion and non-inclusion behavior and have high solubility for poor soluble drugs. These little sponges will flow into round the body till they realize binding surface and begins to unleash the drug. They can load both hydrophobic and hydrophilic drugs. They are simple to produce and are biologically safe. They can load each hydrophobic and hydrophilic medicine. They will be ready by cross linking differing kinds of cyclodextrins with a cross linker. Nanosponge technology has been explored for numerous applications like sustained unharness drug delivery system and delivery of medicine into the oral, epithelial duct further as topical routes. Nanosponges also can be used for unharness of enzymes, vaccines, proteins, antibodies and as a carrier for biocatalysts.

Keywords: Nanosponges; Cross Linking Agent; Cyclodextrins



  1. Trotta F., et al. “Cyclodextrin-based nanosponges as drug carriers”. Beilstein Journal of Organic Chemistry 8 (2012): 2091-2099.
  2. Subramanian S., et al. “Nanosponges: a novel class of drug delivery system-review”. Journal of Pharmacy and Pharmaceutical Sciences 1 (2012): 103-111.
  3. Swaminathan S., et al. “Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effects on solubilization of a model drug”. Journal of Inclusion Phenomena and Macrocyclic Chemistry 76 (2012): 201-211.
  4. Patel EK and Oswal RJ. “Nanosonge and microsponges: a novel drug delivery system”. International Journal of Research in Pharmacy and Chemistry 2 (2012): 237-244.
  5. Swaminathan S., et al. “Nanosponge-aided drug delivery: a closer look”. Pharmaceutical Formulation and Quality (2012): 12-15.
  6. Shinde G., et al. “Current status of colloidal system (nano range)”. International Journal of Drug Research and Technology 6 (2011): 39-54.
  7. Szejtli J. “Cyclodextrin technology”. Berlin: Springer Science and Business Media (1988): 450.
  8. Trotta F., et al. “Cross-linked polymers based on cyclodextrins for removing polluting agents” (2003).
  9. Trotta F and Cavalli R. “Characterization and application of new hyper cross-linked cyclodextrins”. Compos Interfaces 16 (2009): 39-48.
  10. Lembo D and Cavali R. “Nanoparticulate delivery systems for antiviral drugs”. Antiviral Chemistry and Chemotherapy 21 (2010): 53-70.
  11. Kumar MH. “Nanosponge: an innovative drug carrier system-a review”. Pharmaceutical Regulatory Affairs 1 (2012): 203.
  12. Swaminathan S., et al. “Formulation of betacyclodextrin based nanosponges of intraconazole”. Journal of Inclusion Phenomena and Macrocyclic Chemistry 1-4 (2007): 89-94.
  13. Cavalli R., et al. “Cyclodextrin-based nanosponges for drug delivery”. Journal of Inclusion Phenomena and Macrocyclic Chemistry 56 (2006): 209-213.
  14. Vavia PR., et al. “Application of nanosponges in drug delivery”. In: Proceedings XIII International cyclodextrin Symposium. Turin, Italy. Berlin: Springer (2006): 207.
  15. Swaminathan S. “Studies on novel dosage forms dissertation”. Mumbai. Mumbai University (2006).
  16. Liang L., et al. “Optimizing the delivery systems of chimeric RNA, DNA oligonucleotides beyond general oligonucleotide transfer”. FEBS Journal 269 (2002): 5753-5758.
  17. Alongi J., et al. “Role of β-cyclodextrin nanosponges in polypropylene photooxidation”. Carbohydrate Polymer 86 (2011): 127-135.
  18. Cavali R., et al. “Cyclodextrin-based as a vehicle for antitumoral drugs”. WO 2009/003656 A1 (2009).
  19. Trotta F., et al. “Ultrasound-assisted synthesis of cyclodextrin-based nanosponges”. EP 1786 841 B1. (2007).
  20. Sharma R., et al. “Evaluation of the kinetics and mechanism of drug release from econazole nitrate nanosponges loaded carbapol hydrogel”. Indian Journal of Pharmaceutical Education and Research 1 (2011): 25-31.
  21. Sharma R and Pathak K. “Polymeric nanosponges as an alternative carrier for improved retention of econazol nitrate onto the skin through topical hydrogel formulation”. Pharmaceutical Development and Technology 164 (2011): 367-376.
  22. Lala R., et al. “Current trends in β-cyclodextrin based drug delivery systems”. International Journal of Research in Ayurveda and Pharmacy 5 (2011): 1520-1526.
  23. Gurusalkar T., et al. “Cyclodextrin based nanosponges for pharmaceutical use. A review”. Acta Pharmaceutica 88 (2013): 335-358.
  24. Sinko P. “Martin’s physical pharmacy and pharmaceutical sciences (5th Ed.)”. Philadelphia: Lippincott Williams and Williams Publishers.
  25. Ansari K., et al. “Cyclodextrin-based nanosponges for delivery of resveratrol: In vitro characterisation, stability, cytotoxicity and permeation study”. AAPS PharmSciTech 12 (2011): 279-286.
  26. Cavalli R., et al. “5-Fluorouracile loaded -cyclodextrin nanosponges: in vitro characterization and cytotoxicity”. In Proceedings XIII international cyclodextrin symposium (2006): 207.
  27. Torne S J., et al. “Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges”. Drug Delivery 17 (2010): 419-425.
  28. Yurtdas G., et al. “Inclusion complexes of fluconazole with b-cyclodextrin: Physicochemical characterization and in vitro evaluation of its formulation”. Journal of Inclusion Phenomena and Macrocyclic Chemistry 70 (2011): 429-435.
  29. Loftsson T., et al. “Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs”. Die Pharmazine 59 (2004): 25-29.
  30. Magnusdottir A., et al. “Cyclodextrins”. Journal of Inclusion Phenomena and Macrocyclic Chemistry 44 (2002): 213-218.
  31. Trotta F., et al. “Cyclodextrin-based Nanosponges as a Vehicle for Antitumoral Drugs”. WO 2009/003656 A1 (2009).
  32. Bivas-Benita M., et al. “PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium”. European Journal of Pharmaceutics and Biopharmaceutics 58 (2004): 1-6.
  33. Galindo-Rodriguez S., et al. “Physicochemical parameters associated with nanoparticle formation in the salting-out: Emulsification-diffusion and nanoprecipitation methods”. Pharmaceutical Research 21 (2004): 1428-1439.
  34. Jeong Y., et al. “Effect of cryoprotectants on the reconstitution properties of surfactant-free nanoparticles of poly (d,l-lactide-co-glycolide)”. Journal of Microencapsulation 22 (2005): 593-601.
  35. Layre A., et al. “Nanoencapsulation of a crystalline drug”. International Journal of Pharmaceutics 298 (2005): 323-327.
  36. Redhead H M., et al. “Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation”. Journal of Controlled Release 70 (2001): 353-363.
  37. Pecora R. “Dynamic light scattering measurement of nanometer particles in liquids”. Journal of Nanoparticle Research 2 (2002): 123-131.
  38. Stephenson G A. “Applications of x-ray powder diffraction in the Pharmaceutical industry”. The Rigaku Journal 22 (2005): 2-15.
  39. Brittain H G., et al. “Physical characterization of pharmaceutical solids”. Pharmaceutical Research 8 (1991): 963-973.
  40. Sherje AP., et al. “Cyclodextrin-based nanosponges: A critical review”. Carbohydrate Polymers 173 (2017): 37-49.
  41. Jain A., et al. “Engineered nanosponges as versatile biodegradable carriers: An insight”. Journal of Drug Delivery Science and Technology 57 (2020): 101643.
  42. Ranucci E., et al. “Cross-linked resins by stepwise polyaddition of β-cyclodextrin with bisacrylamides and assessment of their potential as ph- sensitive NPs for site-specific protein delivery”. Proceedings CRS (2012): 15-17.
  43. Trotta F., et al. “Cyclodextrin-based nanosponges as drug carriers”. Beilstein Journal of Organic Chemistry1 (2012): 2091-2099.
  44. Swaminathan S., et al. “Nanosponges encapsulating dexamethasone for ocular delivery: formulation design, physicochemical characterization, safety and corneal permeability assessment”. Journal of Biomed Nanotechnology6 (2013): 998-1007.
  45. Jaque D., et al. “Nanoparticles for photothermal therapies”. Nanoscale16 (2014): 9494-9530.
  46. Cavalli R., et al. “Nanosponge formulation as oxygen delivery systems”. International Journal of Pharmaceutics 1-2 (2010): 254-257.
  47. Hu CMJ., et al. “A biomimetic nanosponge that absorbs pore-forming toxins”. Nature Nanotechnology5 (2013): 336.


Citation: Tiwari Shailee Vijay., et al. “Nanosponges: An Innovative Class of Drug Delivery System - Review". Acta Scientific Pharmaceutical Sciences 5.11 (2020): 09-18.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US